articles
binethepredictionoftwoseparateSVMclassi ersforeachofthemultiplekinases,wastestedbyusingthemtosearchdual-inhibitorsofcombinationsof9anticancerkinasetargetsEGFR,VEGFR,PDGFR,FGFR,Src,Lck,CDK1,CDK2,andGSK3.Thesekinasetargetswereselectedbecauseoftheirtherapeuticrelevanceandtheavailabilityofsuf cientnumberoftheknowninhibitorsanddual-inhibitors.The rstsixkinasesbelongtotheproteinkinasegroupPTKgroup,andthelastthreebelongtotheCMGCgrouprespectively.Basedondual-inhibitoravailability,wefocusedon11kinasepairsEGFR-PDGFR,EGFR-FGFR,EGFR-Src,VEG-FR-Lck,PDGFR-FGFR,PDGFR-Src,Src-Lck,CDK1-CDK2,CDK1-GSK3,CDK2-GSK3,andCDK1-VEGFR.The rst7kinasepairsareintra-PTKgroup,theeighthto10thareintra-CMGCgroup,andthe11thareinter-PTK-CMGCgroupkinasepairsrespectively,representativeofdifferenttypesofkinasepairs.Thesekinasepairsarefrequentlycoexpressedorcoactivatedinvariouscancers,22,23andtargetedbymultitargetagents9,10withgoodanticanceref cacies.InhibitorsofgrowthfactorreceptortyrosinekinasesEGFR,VEGFR,PDGFRandFGFRhavebeensuccessfullyusedforcancertreatments.10,24-28EGFRpro-motesproliferationandsurvival.24VEGFRregulatesangio-genesisandsurvival.26PDGFRmodulatesangiogenesisandgrowth,andisoneofthemultitargetsofseveralapprovedandclinicaltrialdrugs.10,27FGFRregulatesangiogenesisandcancerprogression,andisoneofthemultitargetsofseveralclinicaltrialdrugs.10,28Src-familykinasesSrcandLckmodulatemultiplepathwaysofcellgrowth,differentiation,migrationandsurvival,andarepartofthemultitargetsofseveralmarketedandclinicaltrialdrugs.10,29CDKspromotecellcycleprogression,theirinhibitionseverelylimitstheaberrantcell-cycleprocessintumorandinducesapoptosis,
(22)Gockel,I.;Moehler,M.;Frerichs,K.;Drescher,D.;Trinh,T.T.;
Duenschede,F.;Borschitz,T.;Schimanski,K.;Biesterfeld,S.;Herzer,K.;Galle,P.R.;Lang,H.;Junginger,T.;Schimanski,C.C.Co-expressionofreceptortyrosinekinasesinesophagealadenocarcinomaandsquamouscellcancer.Oncol.Rep.2008,20(4),845–50.
(23)Stommel,J.M.;Kimmelman,A.C.;Ying,H.;Nabioullin,R.;
Ponugoti,A.H.;Wiedemeyer,R.;Stegh,A.H.;Bradner,J.E.;Ligon,K.L.;Brennan,C.;Chin,L.;DePinho,R.A.Coactivationofreceptortyrosinekinasesaffectstheresponseoftumorcellstotargetedtherapies.Science2007,318(5848),287–90.
(24)Speake,G.;Holloway,B.;Costello,G.Recentdevelopments
relatedtotheEGFRasatargetforcancerchemotherapy.Curr.Opin.Pharmacol.2005,5(4),343–9.
(25)Moasser,M.M.TargetingthefunctionoftheHER2oncogenein
humancancertherapeutics.Oncogene2007,26(46),6577–92.(26)Zhong,H.;Bowen,J.P.Moleculardesignandclinicaldevelop-mentofVEGFRkinaseinhibitors.Curr.Top.Med.Chem.2007,7(14),1379–93.
(27)Lewis,N.L.Theplatelet-derivedgrowthfactorreceptorasa
therapeutictarget.Curr.Oncol.Rep.2007,9(2),89–95.
(28)Rusnati,M.;Presta,M.Fibroblastgrowthfactors/ broblastgrowth
factorreceptorsastargetsforthedevelopmentofanti-angiogenesisstrategies.Curr.Pharm.Des.2007,13(20),2025–44.
(29)Benati,D.;Baldari,C.T.SRCfamilykinasesaspotential
therapeutictargetsformalignanciesandimmunologicaldisorders.Curr.Med.Chem.2008,15(12),1154–65.1548
MOLECULARPHARMACEUTICSVOL.7,NO.5
Maetal.
andCDKinhibitorsarebeingdevelopedandtestedinclinicaltrialsforanticancertherapeutics.30GSK3modulatesglucosemetabolismandthefunctionofvariousproteins,andisassociatedwithneurodegenerativediseases,stroke,bipolardisorder,diabetesandcancer.31GSK3inhibitorshavestartedtoreachclinicaldevelopmentforthetreatmentofvariousdisorders.31
MultitargetVSperformancewastestedbyarigorousmethodthatassumesnoexplicitknowledgeofknownmultitargetagents,becausethenumberofknownmultitargetagentsisgenerallysmallformanytargetpairs.TheSVMofeachkinasewastrainedbyusingnon-dual-inhibitorsofthatkinase.ThecollectiveyieldofC-SVMofeachkinasepair(percentofknowndual-inhibitorsidenti edasdual-inhibitors)wasestimatedbyusingknowndual-inhibitorsofeachkinasepair.TargetselectivityofeachC-SVMwasassessedbyusingnon-dual-inhibitorsofthekinasepairandinhibitorsoftheother7kinases,outofthe9evaluatedkinases,notincludedinthekinasepair.Virtual-hitratesandfalse-hitratesinsearchinglargecompoundlibrarieswereevaluatedbyusing13.56millionPubChemcompounds,168thousandcompoundsfromtheMDLDrugDataReport(MDDR)database,and276-3,806MDDRcompoundssimilarinstructuralandphysicochemicalpropertiestotheknowndual-kinaseinhibitors.MDDRcontainsbiologicallyrelevantcompounds(activeagainstindividualmoleculartargetorbiologicalassay)andwell-de nedderivativesreportedinthepatentliterature,journals,meetingsandcongresses.PubChemandMDDRcontainhighpercentagesofinactiveoractivecompoundssigni cantlydifferentfromthedual-inhibitors,andtheeasilydistinguishablefeaturesmaymakeVSenrichmentsarti ciallygood.32Therefore,VSperformanceismorestrictlytestedbyusingasubsetofMDDRcompoundssimilartothedual-inhibitorssothatenrichmentisnotsimplyaseparationoftrivialphysico-chemicalfeatures.33
VSperformanceofC-SVMwasfurthercomparedwiththatofthreeVSmethods,whichincludetwopopularmoleculardockingsoftwareSur ex-DockandDOCKversion3.5.54attheDOCKBlasterserver,34asimilarity-based
(30)Schwartz,G.K.;Shah,M.A.Targetingthecellcycle:anew
approachtocancertherapy.J.Clin.Oncol.2005,23(36),9408–21.
(31)Medina,M.;Castro,A.Glycogensynthasekinase-3(GSK-3)
inhibitorsreachtheclinic.Curr.Opin.DrugDiscoVeryDeV.2008,11(4),533–43.
(32)Verdonk,M.L.;Berdini,V.;Hartshorn,M.J.;Mooij,W.T.;
Murray,C.W.;Taylor,R.D.;Watson,P.Virtualscreeningusingprotein-liganddocking:avoidingarti cialenrichment.J.Chem.Inf.Comput.Sci.2004,44(3),793–806.
(33)Huang,N.;Shoichet,B.K.;Irwin,J.J.Benchmarkingsetsfor
moleculardocking.J.Med.Chem.2006,49(23),6789–801.(34)Irwin,J.J.;Shoichet,B.K.;Mysinger,M.M.;Huang,N.;Colizzi,
F.;Wassam,P.;Cao,Y.Automateddockingscreens:afeasibilitystudy.J.Med.Chem.2009,52(18),5712–20.
Synthesis and Characterization of Pyrazoleanthrone Derivatives as Aurora A Kinase Inhibitors_生产/经营管理_经管营销_专业资料。Chem.Res.Chin.Univ.2013.29(6)...
Synthesis and Characterization of Pyrazoleanthrone Derivatives as Aurora A Kinase Inhibitors_生产/经营管理_经管营销_专业资料。Chem.Res.Chin.Univ.2013.29(6)...
热门文档